XBP1u protein levels are decreased in VSMCs treated with high phosphate, human and mouse arteries with chronic renal failure (CRF)XBP1u inhibits calcification in A7r5, rat primary VSMCs, and human aortic SMCsXBP1u directly binds to β‐catenin and inhibits β‐catenin/ TCF transcriptional activity and the target genes Runx2 and Msx2. This evidence concerns the gene HNF4A and chronic kidney disease.